CG Oncology (CG Oncology) FCF Yield % : -1.81 (As of Jun. 07, 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, CG Oncology's Trailing 12-Month Free Cash Flow is $-42.09 Mil, and Market Cap is $2,325.74 Mil. Therefore, CG Oncology's FCF Yield % for today is -1.81%.

The historical rank and industry rank for CG Oncology's FCF Yield % or its related term are showing as below:

CGON' s FCF Yield % Range Over the Past 10 Years
Min: -3.73 Med: -1.99 Max: -1.01
Current: -1.81

During the past 3 years, the highest FCF Yield % of CG Oncology was -1.01%. The lowest was -3.73%. And the median was -1.99%.

CGON's FCF Yield % is ranked better than
79.6% of 1554 companies
in the Biotechnology industry
Industry Median: -14.135 vs CGON: -1.81

CG Oncology's FCF Margin % for the quarter that ended in Mar. 2024 was -4,919.47%.

CG Oncology FCF Yield % Historical Data

The historical data trend for CG Oncology's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology FCF Yield % Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

FCF Yield %

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial			-	-	-	-	-3.56

Competitive Comparison of CG Oncology's FCF Yield %

For the Biotechnology subindustry, CG Oncology's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's FCF Yield % distribution charts can be found below:

* The bar in red indicates where CG Oncology's FCF Yield % falls into.

CG Oncology FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

CG Oncology's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-45.679	/	0
	=	N/A%

CG Oncology's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-26.024	*	4	/	2925.33357
	=	-3.56%

CG Oncology FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

CG Oncology FCF Yield % Related Terms

Thank you for viewing the detailed overview of CG Oncology's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024